The use of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes: A quantitative benefit-risk analysis

被引：0
|
作者：
D'Souza, Lynn [1 ]
Alkabbani, Wajd [2 ]
Gamble, John-Michael [2 ]
机构：
[1] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada
[2] Univ Waterloo, Waterloo, ON, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
641
引用
收藏
页码：300 / 301
页数：2
相关论文
共 50 条
  • [21] Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
    Kohei Kaku
    Koichi Kisanuki
    Mari Shibata
    Takashi Oohira
    Drug Safety, 2019, 42 : 1311 - 1327
  • [22] Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
    Gallwitz, Baptist
    DRUG SAFETY, 2010, 33 (02) : 87 - 100
  • [23] Pattern of Statin use in patients with diabetes mellitus type 2 for primary and secondary prevention of cardiovascular disease in Saudi Arabia
    Ismail, Hussein M.
    Shora, Hassan A.
    Al-Nozha, Omar
    Yamany, Hussain A.
    Al-Nozha, Fareed
    Zaitone, Sawsan A.
    Alahmdi, Hussam
    Aljohani, Abdulsalam
    Almohammadi, Nawaf
    Abdallah, Ayat R.
    AFRICAN JOURNAL OF DIABETES MEDICINE, 2020, 28 (02):
  • [24] Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes
    Scheen, A. J.
    Paquot, N.
    DIABETES & METABOLISM, 2013, 39 (03) : 179 - 190
  • [25] Cardiovascular risk stratification in overweight or obese patients in primary prevention. Implications for use of statins
    Masson, Walter
    Lobo, Martin
    Huerin, Melina
    Molinero, Graciela
    Manente, Diego
    Pangaro, Mario
    Vitagliano, Laura
    Zylbersztejn, Horacio
    ENDOCRINOLOGIA Y NUTRICION, 2015, 62 (02): : 83 - 90
  • [26] Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
    Baptist Gallwitz
    Drug Safety, 2010, 33 : 87 - 100
  • [27] Statin Therapy: Diabetes Mellitus Risk and Cardiovascular Benefit in Primary Prevention
    Porath, Avi
    Arbelle, Jonathan Eli
    Fund, Naama
    Cohen, Asaf
    Mosseri, Morris
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2018, 20 (08): : 480 - 485
  • [28] Do type 2 diabetes patients require acetylsalicylic acid for primary prevention of cardiovascular disease?
    Pavlicek, V.
    DIABETOLOGE, 2008, 4 (08): : 655 - 656
  • [29] The Use of Statins in the Primary Prevention of Cardiovascular Disease: A Combined Analysis of Nine Randomized Controlled Trials
    Brugts, Jasper J.
    Yetgin, Tuncay
    Hoeks, Sanne
    van Domburg, Ron
    Deckers, Jaap W.
    CIRCULATION, 2008, 118 (18) : S1150 - S1150
  • [30] Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?
    Leggio, M.
    Bendini, M. G.
    Caldarone, E.
    Lombardi, M.
    Severi, P.
    D'Emidio, S.
    Stavri, D. C.
    Armeni, M.
    Bravi, V.
    Mazza, A.
    DIABETES & METABOLISM, 2018, 44 (03) : 217 - 225
12345